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Of all diagnosed pregnancies, 10 - 15% end in 
spontaneous mis carriage (SM).[1] Chromosomal 
abnormalities are the most common cause, more than 
50% of aborted fetuses in the first trimester showing 
numerical abnormalities including trisomies, X 
monosomies and tripoidies. Aneuploidies become less prevalent as 
pregnancy progresses (30% in the second trimester), because most 
abnormal fetuses have miscarried earlier. A number of other factors 
(maternal factors, infections, etc.) may also play a role.[2,3]
Cytogenetic analysis of fetal tissue after SM is recommended for 
prognostic and diagnostic purposes, and to give a better estimate of the 
risk of recurrence in future pregnancies. It enables detection of possible 
unbalanced segregation associated with advanced maternal age or 
the presence of balanced structural rearrangement.[3,4] Conventional 
karyotyping has been the gold standard for the cytogenetic analysis 
of products of SM. However, SM products in the first trimester 
are often collected at advanced stages of maceration as a result of 
tissue disintegration of the dead fetus in utero, which may cause 
significant DNA damage, or are haemorrhagic samples contaminated 
with maternal blood. Because karyotype analysis requires cell culture 
to obtain metaphase spreads, the poor quality of SM products often 
means that it is impossible to obtain a result because of culture failure, 
or that results are invalid due to maternal cell contamination (MCC).
Some molecular cytogenetic approaches such as FISH (fluorescence 
in situ hybridisation), MLPA (multiplex ligation probe amplification) 
and QF-PCR (quantitative fluorescence-polymerase chain reaction) 
have been described as valuable in the cytogenetic analysis of SM 
products.[5-7] Performed within 24 - 48 hours, as opposed to weeks 
for karyotyping, these do not require cell culture, and DNA can be 
analysed directly after it is extracted. However, while it is possible 
to investigate several regions with FISH, the number of regions that 
can be explored with QF-PCR is limited, and MLPA requires the 
use of two commercial kits to invesigate subtelomere regions.[8] An 
additional approach is array-comparative genomic hybridisation 
(CGH), which has a better diagnostic yield than conventional 
karyotyping in the screening of products of conception (POC)[1] but 
with the disadvantage of high cost.
A new rapid method for the detection of whole-chromosome 
aneuploidies, based on a BACs-On-BeadsTM technology (Perkin 
Elmer, Finland), has recently been introduced. Two assays are 
available, Prenatal BoBsTM for the detection of trisomy 13, 18, and 21 
and the most frequent syndromes associated with microdeletions, and 
KaryoLite BoBsTM, which can detect aneuploidy in all chromosomes 
by quantifying the proximal and terminal regions of each chromosome 
arm. Prenatal BoBsTM has been shown to be a robust technology for 
the prenatal investigation of fetuses with or without abnormalities on 
ultrasound,[5,9] whereas KaryoLite BoBsTM has been found clinically 
useful for the investigation of SM products.[10]
Since September 2012, Prenatal BoBsTM has been used for prenatal 
diagnosis in the routine clinical setting in the Medical Cytogenetic 
Service of the University Hospital of Clermont-Ferrand (France). 
We describe our clinical experience of the screening of SM products 
collected at the university hospitals of Clermont-Ferrand and Sidi Bel 
Abbès (Western Algeria) using Prenatal BoBsTM.
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Background. Fifty percent of spontaneous miscarriages (SMs) are attributed to chromosomal abnormalities. Cytogenetic analysis is 
an important tool for patient counselling and assessment of the risk of recurrence in future pregnancies. Conventional karyotyping 
has been the gold standard for chromosomal investigation of products of conception (POC), but it has limitations due to sample 
maceration, culture failure and maternal cell contamination. Molecular cytogenetic approaches have therefore been developed and 
found valuable in the cytogenetic investigation of these samples. The Prenatal BoBsTM and KaryoLite BoBsTM, based on the newly 
developed BACs-on-BeadsTM technology, have been described as reliable tests for rapid detection of aneuploidies in prenatal and 
POC samples, respectively.
Objective. To describe our clinical experience of routine screening of POC samples with Prenatal BoBsTM, the test used by our laboratory in France.
Methods. Seventeen samples collected at the University Hospital of Sidi Bel Abbès (Western Algeria) and a further 60 from the University 
Hospital of Clermont-Ferrand (France) were analysed (19 chorionic villi from products of curettage, 12 placentas, 9 amniotic cells and 37 
biopsy specimens). All were screened for the frequent aneuploidies (chromosomes 13, 18, 21, X and Y) in addition to nine microdeletion/
microduplication syndrome regions by Prenatal BoBsTM. Standard karyotyping was performed on 51 samples, but failed in 38 cases.
Results. Prenatal BoBsTM identified one trisomy 21 and one deletion of 17p13.3. Furthermore, it provided a conclusive result in cases of 
culture failure (n=38) and in samples with macerated tissue (n=19). The overall failure rate was 11.4%.
Conclusions. Prenatal BoBsTM is a promising technology that represents a fast, sensitive and robust alternative to routine screening for 
chromosomal abnormality in products of SM. Furthermore, it overcomes the limitations of conventional karyotyping and current molecular 
cytogenetic techniques.
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Patients and methods
Biological samples and DNA 
extraction
Seventeen POC were collected after SMs in 
the maternity department of the Hassani 
Abdelkader University Hospital of Sidi Bel 
Abbès, and 60 additional samples were collected 
at the University Hospital of Clermont-Ferrand 
after medical abortion due to suspicion of a 
molar pregnancy (n=1), spontaneous abortion 
(n=8) or fetal death in utero (n=51). Samples 
included chorionic villi from products of 
curettage (n=19), placenta (n=12), amniotic 
cells (n=9) and biopsy specimens (n=37).
Gestational ages ranged from 5 to 40 weeks 
(mean 21.5): 17 specimens were from the first 
trimester (5 - 12 weeks), 35 from the second 
trimester (13 - 24 weeks) and 25 from the 
third trimester (25 - 41 weeks). Women who 
had SMs were between 19 and 43 years of 
age (mean 30.3), 23.3% being of advanced 
maternal age (≥35). All women provided 
written consent.
Placental chorionic villi from maternal 
decidua, blood clots and mucus were dissected 
under a dissecting microscope into fragments 
a few millimetres in size. DNA was obtained 
from chorionic villus cells, amniotic cells 
or fetal skin fibroblasts without cell culture 
using the QIAamp DNA Mini Kit (Qiagen, 
Germany).
Prenatal BoBs™ assay
All the samples collected were analysed using 
the Prenatal BoBsTM kit. Fig. 1 shows the 
main steps of the assay. Prenatal BoBsTM is 
a multiplex bead-based suspension array 
technology designed for gain-and-loss 
screening of chromosomes 13, 18, 21, X and 
Y and nine targeted microdeletion regions. 
It uses the LuminexTM xMAPTM technology 
(Luminex Corp., USA), a multiplexing tech-
nology utilising polystyrene beads approxi-
mately 5 μm in diameter that have been 
impregnated with a specific ratio of two 
different fluorescent dyes. Ten concentrations 
of both dyes were used, and a range of >100 
different dye/bead combinations with distinct 
fluorescent signatures or spectral addresses 
that can be identified through excitation 
of the impregnated dyes when read by the 
LuminexTM analyser was created. In Prenatal 
BoBsTM, each bead was coupled with bacterial 
artificial chromosomes (BACs) derived from 
chromosome regions of interest. Using a flow 
cytometry approach, each bead was read by 
two separate lasers in a LuminexTM 100/200TM 
analyser equipped with xPONENT 3.1 
software. The BoBsoftTM software generated 
a ‘Results tab’ with a numerical and graphical 
representation of the fluorescent probe ratio 
v. female and male references. A sample 
was defined as ‘normal disomic’ when the 
fluorescent ratio was ~1.0 for all loci analysed. 
Where deletions or duplications were present, 
probe ratios were outside the normal expected 
ratio range determined by the software for 
each sample.
The contents of the Prenatal BoBsTM kit 
were sufficient for 96 reactions. This assay 
was used for the rapid detection of gains 
and losses of DNA in 75 regions, including 
aneuploidies of chromosomes 13, 18, 21, X 
and Y, as well as gains and losses in nine 
microdeletion syndrome regions that are often 
associated with genetic disorders. Eighty-three 
BAC probes were used in the Prenatal BoBsTM 
panel: five for each of chromosomes 13, 18, 21, 
Table 1. Microdeletion syndromes with the chromosomal regions targeted by Prenatal BoBs™
Aneuploidies/microdeletion 
syndromes Target chromosomal region Number of probes
Wolf-Hirschhorn syndrome 4p16.3 5
Cri du chat syndrome 5p15.3-p15.2 8
Williams-Beuren syndrome 7q11.2 5
Langer-Giedon syndrome 8q23-q24 7
Prader Willi/Angelman syndrome 15q11-q12 7
Miller-Dieker syndrome 17p13.3 6
Smith-Magenis syndrome 17p11.2 4
Di George 1 syndrome 22q11.2 4
Di George 2 syndrome 10p14 4
Patau syndrome (trisomy 13) 13q13.3-q21.2 5
Edwards syndrome (trisomy 18) 18p11.32-q22.1 5
Down syndrome (trisomy 21) 21q22.11-q22.3 5
Aneuploidy of chromosome X Xp22.31-q27.3 5





















Fig 1. Main steps of the Prenatal BoBsTM assay. Briefly, genomic DNA is labelled with biotin, purified 
and hybridised to BACs-on-BeadsTM probes. Then the reporter molecule (streptavidin-phycoerythrin) 
is bound to biotin-labelled DNA. Thereafter, fluorescent signals are measured with the LuminexTM 
100/200 and data are analysed with BoBSoftTM software.
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X and Y, four to eight each for the nine well-defined target loci, and six 
autosomal controls, as shown in Table 1.
Selection of the nine microdeletion syndrome regions was based 
on their association with chromosomal disorders with a relatively 
high prevalence, and syndromes in which the deletion was the major 
mechanism underlying the pathology. Deletions of these regions are 
generally not detectable or may be missed by conventional karyotyping. 
The syndromes have well-described phenotypes and known clinical 
significance.[11]
Results
We attempted analysis using Prenatal BoBsTM in 70 of the 77 samples 
collected. Of the remaining seven, six were empty gestational sacs, 
haemorrhagic samples with MCC or macerated samples with absence 
of chorionic villi; the last sample was excluded owing to a low DNA 
amount after DNA extraction (<5 ng/μL).
Cytogenetic analysis using Prenatal BoBsTM gave a conclusive result for 
62 of the 70 samples (88.6%). Failure to deliver a result in the remaining 
eight cases (11.4%) was due to poor DNA quality. Of the 62 samples, 60 
were considered normal (96.8%) and two had abnormal results (3.2%) 
(Table 2): one trisomy 21 (intrauterine fetal death at 11 weeks’ gestation), 
and a deletion of 17p13.3 (Miller-Dieker syndrome, MDS) (Fig. 2).
Standard karyotyping was not attempted in 26 samples, 19 of which 
were too macerated for cell culture. Karyotyping failed in 38 samples 
because of absence of cell proliferation and microbial contamination in 
the cell cultures. Thirteen samples had normal karyotypes.
Trisomy 21 was detected in a female fetus who died in utero at 11 
weeks’ gestation. At autopsy, the fetus was found to have a hygroma and 
generalised subcutaneous oedema. As the cell culture failed, we could not 
determine whether the trisomy was total or partial.
The deletion of 17p13.3 (MDS) was identified in a female fetus who died 
in utero at 38 weeks’ gestation. MDS is characterised by a developmental 
defect of the brain (type 1 lissencephaly), which is caused by incomplete 
neuronal migration. This microdeletion syndrome is also characterised 
by distinctive facial features and other congenital malformations. Serum 
markers in the first and second trimester were normal and the second 
ultrasound scan revealed a single umbilical artery. At autopsy, the fetus 
was found to be hypotrophied and short in length (<25th percentile) and 
Fig. 2. Prenatal BoBsTM profiles of case 1 (left) and 2 (right). Red spots show sample-to-female references ratios and blue spots sample-to-male references ratios. Arrows 
show the range of (A) normal ratios, and (B) abnormal ratios. C = female gonosome profile showing that the patient has the same number of copies of chromosome X as 
female references (red dots in the normal range) but more than male references (blue dots in amplification), and has the same number of copies of chromosome Y as female 
references (red dots in the normal range) and less than male references (blue dots in deletion). D = 21q22 amplification showing trisomy 21 profile. E = 17p13.3 deletion.
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to have a decreased head circumference (<3rd 
percentile). However, there were no facial 
dysmorphic features or cardiac, pulmonary 
or renal abnormalities. Neuroanatomical 
examination did not show lissencephaly. FISH 
analysis showed that the LIS1 gene, monosomy 
of which is responsible for MDS, was not 
deleted. The deletion was characterised further 
by array genomic comparative hybridisation 
(4 × 180K, Agilent, USA), which showed a 
deletion of 2.3 Mb encompassing 40 genes. 
This deletion, which is not typical of the 
MDS, was probably responsible for the short 
stature of the fetus, but the fact that the single 
umbilical artery could have contributed to 
death could not be excluded.
Discussion
Prenatal BoBsTM is a recently developed 
molecular cytogenetic screening tool for the 
most common aneuploidies (chromosomes 
13, 18, 21, X and Y) and the nine most 
frequent microdeletion syndromes found in 
POC, which are not detectable or may be 
missed by conventional karyotyping. This 
rapid targeted assay is dependent on DNA 
extraction and does not require live or intact 
cells, and represents an interesting alternative 
to conventional cytogenetics that require cell 
culture.[5,9,11,12] In our study, cell culture failure 
prevented standard karyotype analysis of 38 
samples. However, Prenatal BoBsTM provided 
a conclusive result in all cases, making it a 
useful tool for the cytogenetic analysis of 
POCs, especially when culture fails.
We analysed 70 DNA samples extracted 
from chorionic villi of products of SM, skin 
fibroblasts, amniotic cells and products of 
curretage. Eight cases were uninterpretable, 
giving a technical failure rate of 11.4%, which 
was higher than the rate of ~3% registered for 
prenatal screening using Prenatal BoBsTM[5,12] 
and also higher than the rate of ~ 2% reported 
for the screening of POCs using Karyolite 
BobsTM.[6,10] These results may be explained 
by the fact that we had numerous samples 
with poor DNA quality due to advanced 
maceration of fetal tissue.
Among the remaining cases, Prenatal 
BoBsTM revealed the presence of two 
chromosomal abormalities: one case of 
trisomy 21 that could not be detected by 
karyotyping because of cell culture failure 
and was associated with advanced maternal 
age (42 years), a risk factor well known to 
increase the risk of aneuploidies, mostly 
trisomies,[7] and one case of microdeletion of 
17p13.3 (2.3 Mb) that could not be detected 
by karyotyping because of its low resolution, 
or by Karyolite BoBsTM because of limitations 
in the detection of structural rearrangements. 
These structural rearrangements account for 
~6% of abnormalities found in POC.[6] MDS 
is a rare malformation syndrome manifested 
by type I lissencephaly and characteristic facial 
features and associated with a microdeletion of 
chromosome 17pl3.3, which can be detected 
by high-resolution cytogenetic techniques in 
~50% of cases.[13] Cytogenetic investigation 
of 1 599 prenatal samples using Prenatal 
BoBsTM revealed 11 cases of microdeletions 
and microduplications (0.75%), among which 
deletion of 22q11.2 (Di George syndrome) was 
the most frequent abnormality detected.[5]
Prenatal BoBsTM is a targeted assay, so the 
loci of the genome that may have clinical 
relevance in an unbalanced state and that 
are not targeted by the probe set will go 
undetected.[5,9,11] Better coverage throughout 
the genome would lead to the detection of 
additional clinically relevant imbalances, but 
would also identify gains or losses of unknown 
or unclear clinical significance.[11,14] Moreover, 
Prenatal BoBsTM has some limitations in the 
detection of polyploidies (triploidies and 
tetraploidies),[5,9] which account for nearly 
16% of abnormalities found by conventional 
karyotyping of POC.[6]
Another disadvantage of SM products is 
the high rate of MCC. Only a few studies 
have tested the ability of Prenatal BoBsTM 
to identify mosaicism and MCC. It has 
been shown that Prenatal BoBsTM can detect 
mosaicism in fetal tissue at a level of 20 - 
40% abnormal cells or higher,[9,15] and that 
MCC in the fetal tissue becomes apparent at 
a level of 20 - 30% of normal female cells.[11]
Prenatal BoBs has been described as more 
informative than rapid FISH and QF-PCR, 
which screen only frequent aneuploidies.[9] 
This technique also enabled us to provide 
rapid results with conclu sive outcomes within 
24 hours of receipt of the sample,[5,9,11,12] 
which is about half the time of fast FISH 
aneuploidy screening, because it is possible to 
interpret the profiles of several samples in few 
minutes. [5,9] Furthermore, it is cheaper than 
other technologies that are able to detect more 
alterations (array-CGH), being of the same 
order of cost as fast FISH.[9,12]
Conclusion
On analysis of 77 samples of POC collected, 
we found the cause of fetal death in two cases 
using Prenatal BoBsTM technology. One of 
these fetuses had trisomy 21 and the other 
a 17p13.3 deletion, which were missed by 
karyotyping (owing to culture failure in one 
case and low resolution in the second). Prenatal 
BoBsTM appears to be fast, sensitive and a good 
alternative to other conventional technologies 
such as karyotyping in the routine screening of 
SM products, especially when tissue is damaged 
and macerated, preventing cell culture. In 
combination with other molecular approaches, 
use of Prenatal BoBsTM could improve detection 
of chromosomal abnormalities in POCs and 
prove helpful in parental counselling.
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fetal outcome BoBs result
Karyotype 
result
1 42 11 Biopsy/IUFD 47,XX,+21 Failure
2 25 40 Placenta/IUFD 46,XX,del 17p13.3 46,XX
IUFD = intrauterine fetal death.
